Ramchandani Rashmi Virendra 4

What Happened

• Rashmi Virendra Ramchandani, VP and Chief Accounting Officer of BioMarin Pharmaceutical Inc. (BMRN), received a total of 43,830 equity awards on January 20, 2026. The filing reports three grant entries: 18,540 RSUs, 7,070 RSUs, and 18,220 units reported as a derivative award (an option grant). All entries show $0.00 as the acquisition price (typical for grants/awards), so no cash was paid by the insider.

Key Details

• Transaction date: January 20, 2026 (reported on Form 4 filed Jan 22, 2026).
• Grants: 18,540 shares (RSUs) + 7,070 shares (RSUs) + 18,220 derivative units (option grant) = 43,830 total.
• Reported price/value: $0.00 for each grant (price not applicable for RSUs/options).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnotes from the filing:
  • F1: The 18,540 and 7,070 awards are restricted stock units (RSUs) granted Jan 20, 2026.
  • F2: The 18,220 derivative award is an option grant that vests 12/48th on Jan 20, 2027 and 1/48th on the 20th of each month thereafter (25% after one year, remainder monthly over three years).
• Timeliness: Filed two business days after the transaction (Form 4 filed Jan 22 for Jan 20 grants), so the filing appears timely.

Context

• These entries are awards/grants (transaction code A), not open-market purchases or sales; they reflect compensation rather than an immediate market bet. RSUs convert to shares upon vesting and do not involve cash paid by the insider at grant. The option vesting schedule means the option becomes exercisable gradually (25% after one year, then monthly thereafter). Such grants are common in executive compensation and do not by themselves indicate a buy/sell sentiment.